Aurobindo Pharma (NSE:AUROPHARMA) EV-to-Revenue : 2.45 (As of May. 15, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Aurobindo Pharma EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Aurobindo Pharma's enterprise value is ₹676,844 Mil. Aurobindo Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was ₹275,913 Mil. Therefore, Aurobindo Pharma's EV-to-Revenue for today is 2.45.

The historical rank and industry rank for Aurobindo Pharma's EV-to-Revenue or its related term are showing as below:

NSE:AUROPHARMA' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.73 Med: 2.25 Max: 4.22
Current: 2.46

During the past 13 years, the highest EV-to-Revenue of Aurobindo Pharma was 4.22. The lowest was 0.73. And the median was 2.25.

NSE:AUROPHARMA's EV-to-Revenue is ranked worse than
50.97% of 1026 companies
in the Drug Manufacturers industry
Industry Median: 2.4 vs NSE:AUROPHARMA: 2.46

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-15), Aurobindo Pharma's stock price is ₹1168.60. Aurobindo Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was ₹470.42. Therefore, Aurobindo Pharma's PS Ratio for today is 2.48.

Aurobindo Pharma EV-to-Revenue Historical Data

The historical data trend for Aurobindo Pharma's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aurobindo Pharma EV-to-Revenue Chart

Aurobindo Pharma Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EV-to-Revenue

Get a 7-Day Free Trial

2.65

1.22

2.09

1.62

1.20

Aurobindo Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															1.07	1.20	1.69	1.98	2.30

Competitive Comparison of Aurobindo Pharma's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aurobindo Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aurobindo Pharma's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aurobindo Pharma's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aurobindo Pharma's EV-to-Revenue falls into.

Aurobindo Pharma EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aurobindo Pharma's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	676844.458	/	275912.5
	=	2.45

Aurobindo Pharma's current Enterprise Value is ₹676,844 Mil.
Aurobindo Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹275,913 Mil.

Aurobindo Pharma (NSE:AUROPHARMA) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aurobindo Pharma's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	1168.60	/	470.419
	=	2.48

Aurobindo Pharma's share price for today is ₹1168.60.
Aurobindo Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹470.42.

Aurobindo Pharma EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aurobindo Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aurobindo Pharma (NSE:AUROPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aurobindo Pharma Ltd (NSE:AUROPHARMA) » Definitions » EV-to-Revenue

Traded in Other Exchanges

524804:India

Address

Plot No. 1, Survey No. 83/1, Galaxy, Floors: 22-24, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad, TG, IND, 500 032

Website

https://www.aurobindo.com

Aurobindo Pharma Ltd is a specialty and generic drug manufacturing company. The company's product portfolio spans a variety of therapeutic areas. The vast majority of the company's sales are generated in the United States, followed by Europe. Most of Aurobindo's sales are derived from its formulations business, with the rest stemming from its active pharmaceutical ingredient operations. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Aurobindo Pharma (NSE:AUROPHARMA) Headlines

No Headlines